[Pyr1]-Apelin-13, Pro(13C5,15N) TFA
Based on 1 Customer Validation
[Pyr1]-Apelin-13, Pro(13C5,15N) (TFA) is the 13C and 15N labeled isotope of [Pyr1]-Apelin-13(HY-P1033).[Pyr1]-Apelin-13 is a potent and selective endogenous apelin receptor agonist.
For research use only. We do not sell to patients.
- Purity: 99.85%
- Formula: C6413C5H108N2115NO16S.xC2HF3O2
- Molecular Weight:1539.76 (free acid)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
![[Pyr1]-Apelin-13, Pro(13C5,15N) TFA Chemical Structure](https://file.medchemexpress.com/product_pic/hy-p1033s1.gif "Click to View [Pyr1]-Apelin-13, Pro(13C5,15N) TFA Chemical Structure")
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 217082-60-5
-
Appearance Solid
-
Molecular Weight 1539.76 (free acid)
-
Formula C6413C5H108N2115NO16S.xC2HF3O2
-
Color White to off-white
-
SMILES
O=C([C@@H]1CCC(N1)=O)N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CCCCN)C(NCC([15N]3[13C@@H]([13CH2][13CH2][13CH2]3)[13C](N[C@@H](CCSC)C(N4[C@@H](CCC4)C(N[C@H](C(O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)=O)=O)CC6=CN=CN6)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 100 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hajimashhadi Z, et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides. 2017 Feb;61:15-22. [Content Brief]
[2]. Serpooshan V, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98. [Content Brief]
[3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
[Pyr1]-Apelin-13, Pro(13C5,15N) TFA Related Classifications
HY-P1033S1 Related Classifications
Powered by Bioz